INO Inovio Pharmaceuticals Inc
Price (delayed)
$1.92
Market cap
$70.4M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.95
Enterprise value
$16.45M
INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO
Highlights
Inovio Pharmaceuticals's debt has shrunk by 61% YoY and by 4.7% QoQ
INO's EPS is up by 35% year-on-year and by 12% since the previous quarter
The gross profit has dropped by 74% year-on-year but it rose by 7% since the previous quarter
INO's revenue has dropped by 74% year-on-year but it is up by 7% since the previous quarter
The equity has contracted by 42% YoY and by 7% from the previous quarter
INO's quick ratio is down by 27% since the previous quarter and by 22% year-on-year
Key stats
What are the main financial stats of INO
Market
Valuations
Earnings
Shares outstanding
36.67M
Market cap
$70.4M
Enterprise value
$16.45M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.73
Price to sales (P/S)
239.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
75.56
Revenue
$217,756
Gross profit
$217,756
Operating income
-$112.4M
Net income
-$107.25M
EBIT
-$107.08M
EBITDA
-$103.95M
Free cash flow
-$104.51M
Per share
Balance sheet
Liquidity
EPS
-$3.95
EPS diluted
-$3.95
Free cash flow per share
-$3.85
Book value per share
$2.62
Revenue per share
$0.01
TBVPS
$4.17
Total assets
$113.2M
Total liabilities
$44.69M
Debt
$11.87M
Equity
$68.5M
Working capital
$62.5M
Debt to equity
0.17
Current ratio
2.77
Quick ratio
2.7
Net debt/EBITDA
0.52
Margins
Efficiency
Dividend
EBITDA margin
-47,735.2%
Gross margin
100%
Net margin
-49,254.3%
Operating margin
-51,616.9%
Return on assets
-88.8%
Return on equity
-128.7%
Return on invested capital
-150.9%
Return on capital employed
-137.5%
Return on sales
-49,172.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
INO stock price
How has the Inovio Pharmaceuticals stock price performed over time
Intraday
2.67%
1 week
10.34%
1 month
2.13%
1 year
-81.1%
YTD
4.92%
QTD
17.79%
Financial performance
How have Inovio Pharmaceuticals's revenue and profit performed over time
Revenue
$217,756
Gross profit
$217,756
Operating income
-$112.4M
Net income
-$107.25M
Gross margin
100%
Net margin
-49,254.3%
The company's operating margin has shrunk by 198% YoY but it rose by 12% QoQ
The gross profit has dropped by 74% year-on-year but it rose by 7% since the previous quarter
INO's revenue has dropped by 74% year-on-year but it is up by 7% since the previous quarter
INO's operating income is up by 22% YoY and by 6% QoQ
Growth
What is Inovio Pharmaceuticals's growth rate over time
Valuation
What is Inovio Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.73
P/S
239.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
75.56
INO's EPS is up by 35% year-on-year and by 12% since the previous quarter
The stock's price to book (P/B) is 79% less than its 5-year quarterly average of 3.4 and 65% less than its last 4 quarters average of 2.1
The equity has contracted by 42% YoY and by 7% from the previous quarter
INO's revenue has dropped by 74% year-on-year but it is up by 7% since the previous quarter
The P/S is 48% lower than the last 4 quarters average of 462.5 and 35% lower than the 5-year quarterly average of 366.5
Efficiency
How efficient is Inovio Pharmaceuticals business performance
The company's return on invested capital has shrunk by 84% YoY and by 36% QoQ
INO's ROE is down by 49% YoY and by 9% from the previous quarter
INO's return on assets is down by 42% year-on-year and by 6% since the previous quarter
INO's return on sales is up by 11% since the previous quarter
Dividends
What is INO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for INO.
Financial health
How did Inovio Pharmaceuticals financials performed over time
The total assets is 153% greater than the total liabilities
The total assets has declined by 34% year-on-year but it has grown by 6% since the previous quarter
The company's total liabilities rose by 33% QoQ but it fell by 17% YoY
Inovio Pharmaceuticals's debt is 83% lower than its equity
Inovio Pharmaceuticals's debt has shrunk by 61% YoY and by 4.7% QoQ
The equity has contracted by 42% YoY and by 7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.